Profile

Atorvia is pioneering first-in-class peptide therapeutics that treat organ failure, beginning with acute kidney injury (AKI). Affecting one in four cardiac surgery patients, AKI has no effective treatment and leads to severe complications. Its single-dose IV therapy protects kidneys, shortens ICU stays, and reduces hospital costs. Atorvia aims to connect with investors and strategic partners to accelerate preclinical development and achieve IND readiness for its life-saving innovation.

Atorvia logo

Website

atorvia.co

Contact


Event details

Date: December 1 - 5, 2025

Event contact

Patricia Cosgrove
Area Director
USA: Life Sciences

Participants

13 in total